Fig. 3From: A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II studyKaplan-Meier curves for overall survival (OS); the median OS was 22.5 months (95 % confidence interval 19.4–25.9 months) N. at risk, number at riskBack to article page